Market capitalization | $486.07m |
Enterprise Value | $450.53m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 22.07 |
P/S ratio (TTM) P/S ratio | 23.82 |
P/B ratio (TTM) P/B ratio | 1.71 |
Revenue growth (TTM) Revenue growth | -68.45% |
Revenue (TTM) Revenue | $20.41m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
8 Analysts have issued a OmniAb forecast:
8 Analysts have issued a OmniAb forecast:
Sep '24 |
+/-
%
|
||
Revenue | 20 20 |
68%
68%
|
|
Gross Profit | -0.50 -0.50 |
101%
101%
|
|
EBITDA | -61 -61 |
182%
182%
|
EBIT (Operating Income) EBIT | -82 -82 |
110%
110%
|
Net Profit | -63 -63 |
112%
112%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Head office | United States |
CEO | Matthew Foehr |
Employees | 106 |
Founded | 2015 |
Website | www.omniab.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.